Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Afrigen Chief On mRNA Vaccine Candidate, IP Hoops, Market-Shaping Efforts

Executive Summary

Petro Terblanche, managing director of Afrigen Biologics, talks to Scrip about a range of critical issues pertaining to the mRNA COVID-19 vaccine candidate being progressed under the wider WHO-backed technology hub initiative in South Africa and which is based on publicly-available Moderna data. Various tools and approaches are on hand to tackle the labyrinth of patents involved, though the hub, the executive underscores, will not infringe intellectual property rights.

Afrigen Biologics has been in the spotlight after it developed an mRNA COVID-19 vaccine candidate based on publicly available Moderna, Inc. data. The Cape Town-based firm’s efforts are part of a wider World Health Organization-backed mRNA vaccine technology hub initiative in South Africa.

Afrigen’s managing director, Petro Terblanche, discusses with Scrip plans to progress the candidate, collaboration discussions with firms across countries including in the US and Canada, and production scale-up challenges. There have also been "outreach" efforts from companies in India and also China, she noted.

Terblanche outlined the various options and tools to traverse the complex intellectual property rights landscape for mRNA vaccines but underscored that the hub and the WHO have no intent to infringe patents.

“I think this is the one part that challenges all our cognitive capabilities. There are many players, many patents. There are composition patents, process patents, design patents – it’s a very complex landscape,” she explained. Listen to the full interview to hear what more she had to say.

Podcast Time Stamps

00:08 Introduction

02:28 Testimony To Scientific Excellence In South Africa

04:35 Engaging With the US NIH, Scientists In Australia, Europe 

06:01 No Assistance Yet From Moderna Or Pfizer/BioNTech

08:23 Scale Up Challenges

9:35 Outreach From Companies In India

12:32 Market Shaping, Procurement Systems

14:29 IP Landscape Is Complex

 

 

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Related Stories:

https://scrip.pharmaintelligence.informa.com/SC145852/Yes-We-Can-South-African-Scientists-On-Their-Way-With-mRNA-Vaccine

https://pink.pharmaintelligence.informa.com/PS145749/Need-For-Skilled-Workforce-A-Key-Issue-In-Countries-Using-mRNA-Tech-Transfer

https://pink.pharmaintelligence.informa.com/PS145732/Coronavirus-Notebook-Six-African-Countries-To-Produce-mRNA-Vaccines-CEPI-Funds-Indian-Candidates

https://invivo.pharmaintelligence.informa.com/IV125010/Calls-For-COVID-Patent-Waivers-Persist-As-Pooling-Initiatives-Plough-Ahead

https://pink.pharmaintelligence.informa.com/PS145491/Year-Of-IP-From-The-TRIPS-Waiver-Proposal-To-The-Moderna-NIH-Patent-Tussle

https://scrip.pharmaintelligence.informa.com/SC144961/Indian-Biotech-In-mRNA-Push-As-COVID-19-Vaccine-Moves-To-Phase-II

https://generics.pharmaintelligence.informa.com/GB151643/South-Africa-Must-Revoke-Key-COVID19-Patents-Says-MSF

https://scrip.pharmaintelligence.informa.com/SC145493/China-mRNA-Player-Abogen-Gets-$300m-More-As-Country-Eyes-Omicron-Threat

 


Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel